{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:59:04Z","timestamp":1761764344758},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":5531,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1093\/annonc\/mdh429","type":"journal-article","created":{"date-parts":[[2004,11,2]],"date-time":"2004-11-02T15:30:00Z","timestamp":1099409400000},"page":"1613-1621","source":"Crossref","is-referenced-by-count":68,"title":["Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer"],"prefix":"10.1016","volume":"15","author":[{"given":"R.P.","family":"Abratt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Brune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Kliment","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Breza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.P.","family":"Selvaggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Beuzeboc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Demkow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdh429_bb0010","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0090-4295(99)80182-4","article-title":"Hormone-refractory prostate cancer: refining the concept","volume":"46","author":"Scher","year":"1995","journal-title":"Urology"},{"key":"10.1093\/annonc\/mdh429_bb0015","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/107327489800500604","article-title":"Management of hormone-sensitive and hormone refractory metastatic prostate cancer","volume":"5","author":"Rago","year":"1998","journal-title":"Cancer Control"},{"key":"10.1093\/annonc\/mdh429_bb0020","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh429_bb0025","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1023\/A:1008394823889","article-title":"Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?","volume":"11","author":"Culine","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh429_bb0030","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1023\/A:1008315106697","article-title":"Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial","volume":"10","author":"Fields-Jones","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh429_bb0035","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1023\/A:1011141611560","article-title":"Phase II study of vinorelbine in patients with androgen-independent prostate cancer","volume":"12","author":"Oudard","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh429_bb0040","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/S0959-8049(02)00145-4","article-title":"Vinorelbine in androgen-independent metastatic prostate carcinoma\u2013a phase II study","volume":"38","author":"Morant","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdh429_bb0045","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/jnci\/91.1.66","article-title":"The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer","volume":"91","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdh429_bb0050","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/A:1008364222793","article-title":"Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older","volume":"10","author":"Vogel","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh429_bb0055","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/1097-0142(20000615)88:12<2677::AID-CNCR5>3.0.CO;2-B","article-title":"Vinorelbine in elderly patients with inoperable non-small cell lung carcinoma","volume":"88","author":"Buccheri","year":"2000","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh429_bb0060","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1200\/JCO.1999.17.11.3461","article-title":"Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group","volume":"17","author":"Bubley","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh429_bb0065","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh429_bb0070","year":"1979","journal-title":"World Health Organisation. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organisation"},{"key":"10.1093\/annonc\/mdh429_bb0075","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jnci\/91.3.244","article-title":"Post-therapy serum prostate specific antigen level and survival in patients with androgen-independent prostate cancer","volume":"91","author":"Scher","year":"1999","journal-title":"J Nal Cancer Inst"},{"key":"10.1093\/annonc\/mdh429_bb0080","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0022-5347(05)67647-1","article-title":"Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice","volume":"163","author":"Dowling","year":"2000","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdh429_bb0085","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Laudis","year":"1977","journal-title":"Biometrics"},{"key":"10.1093\/annonc\/mdh429_bb0090","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1200\/JCO.1999.17.8.2506","article-title":"Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study","volume":"17","author":"Kantoff","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh429_bb0095","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1200\/JCO.2000.18.7.1440","article-title":"Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone","volume":"18","author":"Small","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh429_bb0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-1-4613-1731-9_6","article-title":"Aminoglutethimide: theoretical considerations and clinical results in advanced prostate cancer","volume":"39","author":"Havlin","year":"1988","journal-title":"Cancer Treat Res"},{"key":"10.1093\/annonc\/mdh429_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/S0959-8049(01)81296-X","article-title":"The efficacy of endocrine combination therapy with aminoglutethimide and hydrocortisone in metastatic prostatic cancer refractory to standard endocrine therapies","volume":"37","author":"Kruit","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdh429_bb0110","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1200\/JCO.1999.17.3.958","article-title":"Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer","volume":"17","author":"Petrylak","year":"1999","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdh429_bb0115","first-page":"90","article-title":"Results of a phase II randomized trial of docetaxel (D), estramustine (E) and prednisone (P)\u2014two schedules\u2014versus mitoxantrone (M) and prednisone (P) in patients with hormone-refractory prostate cancer (HRPC)","volume":"13","author":"Oudard","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh429_bb0120","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/cncr.10350","article-title":"Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen-independent prostate carcinoma","volume":"94","author":"Sinibaldi","year":"2002","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh429_bb0125","first-page":"2509","article-title":"Phase II study of docetaxel, estramustine and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780","volume":"19","author":"Savarese","year":"2001","journal-title":"Cancer and Leukemia Group B. J Clin Oncol"},{"key":"10.1093\/annonc\/mdh429_bb0130","first-page":"23","article-title":"Randomized phase III trial of docetaxel (D)\/estramustine (E) versus mitoxantrone (M)\/prednisone (P) in men with androgen-independent prostate cancer (AIPCA)","volume":"2","author":"Petrylak","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdh429_bb0135","article-title":"A multicenter phase III comparison of docetaxel (D)+prednisone (P) and mitoxantrone (MTZ)+P in patients with hormone-refractory prostate cancer (HRPC)","volume":"23","author":"Eisenberger","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh429_bb0140","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2004.12.001","article-title":"Epothilones: mechanism of action and biologic activity","volume":"22","author":"Goodin","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh429_bb0145","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1023\/A:1012539225493","article-title":"A multicenter randomised phase II study of oral versus intravenous vinorelbine in advanced non-small cell lung cancer","volume":"12","author":"Jassem","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh429_bb0150","first-page":"35","article-title":"Phase II study of oral vinorelbine in first line advanced breast cancer chemotherapy","volume":"21","author":"Freyer","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419475236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419475236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/15\/11\/1613\/536716\/mdh429.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T11:51:27Z","timestamp":1582199487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419475236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["S0923753419475236"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdh429","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2004,11]]}}}